A Phase 3 interventional study of Umeclidinium bromide and Placebo in Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline. Completed at 26 sites in 2 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2020-06-29.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline — 7 open to participants now, 8 under way, 5 of them phase 3. Pulmonary Disease, Chronic Obstructive · GlaxoSmithKline.
Among the 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline, this one is the 74th largest by enrollment of the 236 interventional ones that give a count, is one of 11 that started in 2016, is one of 65 in phase 3, and was the 193rd registered.
5,526 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →7 of the 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States, United Kingdom
Ages 40–80
GlaxoSmithKline · Sites in United States, Argentina
Ages 40–80
GlaxoSmithKline · Sites in United States, Japan
Ages 40–80
GlaxoSmithKline · Sites in United Kingdom
Ages 18–55 · Healthy volunteers
GlaxoSmithKline · Sites in United States, Argentina, Australia and 22 more countries
Ages 40–75
By country, each count listing its studies:
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
276 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 84 · Phase 2 47 · Phase 3 65 · Phase 4 38
First in 2000; this study’s year is marked. 11 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 308 is above the median of 62 across 3,844 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 101 across the 236 interventional studies, 1,248 across the 40 observational. Of the 264 that completed or were terminated, 141 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
2 of the studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06154837GlaxoSmithKlineA Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease | 2026-12-16 |
| NCT07789899GlaxoSmithKlineA Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Two GSK3862995B Formulations in Healthy Participants | 2027-09-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Studies to date provides substantial evidence for the effectiveness for UMEC 62.5 microgram (mcg) as a long term maintenance therapy for the treatment of COPD; this study further evaluates the efficacy and safety of UMEC 62.5 mcg administered once-daily (OD) for 24 weeks via a NDPI compared with placebo in Asian subjects with COPD. Over approximate 27 weeks of entire study duration, 10 study clinic visits will be conducted on an outpatient basis. Pre-screening visit will be conducted for the informed consent form, review demography, COPD history and COPD concomitant medications. Subjects meeting the eligibility criteria at screening will complete a 7 to 14 day Run-in period and will be provided with albuterol/salbutamol as rescue medication on an "as-needed" basis. Further, subjects will be randomized to the UMEC 62.5 mcg or matching placebo in a 1:2 ratio for 24 week treatment period. A follow up for adverse event assessment will be scheduled approximately 7 days after the treatment period or the Early Withdrawal Visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects meeting the eligibility criteria will complete a 7 to 14 day run-in period and will be randomized to receive UMEC Inhalation Powder 62.5 mcg OD over a period of 24 weeks
Drug: Umeclidinium bromide
Subjects meeting the eligibility criteria will complete a 7 to 14 day run-in period and will be randomized to receive matching placebo of UMEC Inhalation Powder OD over a period of 24 weeks
Drug: Placebo
Blended with lactose and magnesium stearate dry white powder of umeclidinium 62.5 mcg to be inhaled via a NDPI
Blended with lactose and magnesium stearate dry white powder to be inhaled via a NDPI
Change From Baseline in Trough (Pre-bronchodilator) Forced Expiratory Volume in 1 Second (FEV1) on Treatment Day 169
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on Treatment Day 169 was defined as the mean of the FEV1 values obtained 23 and 24 hours after dosing on Treatment Day 168 (i.e. at Week 24). Baseline FEV1 is defined as the mean of the two assessments made pre-dose at Visit 2 (Day 1). Change from Baseline was calculated by subtracting the value on-treatment from the Baseline value. Modified intent-to-treat (mITT) Population comprised of all participants randomized to treatment who received at least one dose of the study medication in the treatment period.
Time frame: Baseline (Day 1) and Day 169
Transition Dyspnea Index (TDI) Focal Score at Week 24 (Day 168)
The Baseline Dyspnea Index (BDI) is used to measure the severity of dyspnea in participants at Baseline . The TDI measures changes in dyspnea severity from Baseline, as established by the BDI. TDI is formed of 3 individual scales that assess change in functional impairment, change in magnitude of task and change in magnitude of effort. The instrument is scored on a 7-point scale from -3 (major deterioration) to +3 (major improvement) for each category. Total scores (3 categories) range from -9 to +9 with lower scores indicating more deterioration in the severity of dyspnoea. A change of \>=1 units is considered to be the minimum clinically important difference (MCID) for the TDI.
Time frame: Week 24 (Day 168)
Change From Baseline in Weighted Mean FEV1 Over 0 to 6 Hours Post-dose on Day 1
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Weighted mean FEV1 was calculated over the nominal 0 to 6 hour post dose period. Values from post-dose assessments which were actually before the time of dosing were excluded from the calculation. The 0 hour value is the average value obtained 30 minutes and 5 minutes pre-dose, and both the 0 hour and 6 hour values must be present for a 0- to 6 hour weighted mean to be calculated. The 0 -to 6 hour weighted mean was derived by calculating the area under the FEV1 curve over the nominal time points of 0 hour, 15 and 30 minutes, 1, 3 and 6 hours, using the trapezoidal rule, and then dividing by the actual time between dosing and the 6 hour assessment. Baseline value for FEV1 was calculated from the values measured 30 minutes and 5 minutes pre-dose on Day 1. Change from Baseline was calculated by subtracting the value on-treatment from the Baseline value.
Time frame: Baseline (pre-dose on Day 1) and Day 1 (0 to 6 hours)
Number of Participants With Adverse Events (AE) and Serious AE (SAE)
AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant or is associated with liver injury and impaired liver function.
Time frame: Up to Day 178
Change From Baseline in Vital Sign Parameters: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Vital signs (SBP and DBP) were obtained after participants had rested for approximately 5 minutes and before performing electrocardiogram (ECG) and spirometry testing. A single set of values was obtained. Baseline was the most recent recorded value before dosing on Day 1 at schedule visit. Change from Baseline was calculated by subtracting the value on-treatment from the Baseline value. Anytime post-Baseline values have been presented for SBP and DBP respectively.
Time frame: Baseline (Day 1) to Day 169 (Visit 9)
Change From Baseline in Vital Sign Parameter: Pulse Rate
Vital sign pulse rate was obtained after participants had rested for approximately 5 minutes and before performing electrocardiogram (ECG) and spirometry testing. A single set of values was obtained. Baseline was the most recent recorded value before dosing on Day 1 at schedule visit. Change from Baseline was calculated by subtracting the value on-treatment from the Baseline value. Anytime post-Baseline values have been presented for pulse rate.
Time frame: Baseline (Day 1) to Day 169 (Visit 9)
Number of Participants With Electrocardiogram (ECG) Abnormalities Any Time Post Baseline
A 12-lead ECG measurement was obtained after measurement of vital signs and before spirometry testing. Participants should be placed in the supine position for the ECG measurements. Any ECG abnormality recorded by a participant after the start of study treatment was included in the any-time post-Baseline record of all ECG abnormalities. Partcipants with abnormal ECG interpretation have been presented.
Time frame: Up to Day 169 (Visit 9)
Number of Participants With Hematology Data Outside the Normal Range at Any Time Post-Baseline
Hematology parameters included basophils (normal range 0 to 0.2 giga cells/Liter), eosinophils (0.05 to 0.55 giga cells/Liter), hematocrit (0.36 to 0.49 percentage of red blood cells in blood), hemoglobin (118 to 168 gram/Liter), lymphocytes (0.85 to 4.1 giga cells/Liter), monocytes (0.2 to 1.1 giga cells/Liter), platelet count (PC)(130 to 400 giga cells/Liter), neutrophils (1.8 to 8 giga cells/Liter), total neutrophils (TN) (1.8 to 8 giga cells/Liter), white blood cell \[WBC\] count (3.8 to 10.8 giga cells/Liter). Only categories with non-zero (high and low) values at any time post Baseline have been presented.
Time frame: Up to Day 168 (Visit 8)
Number of Participants With Clinical Chemistry Data Outside the Normal Range at Any Time Post-Baseline
Clinical chemistry parameters assessed included albumin (normal range 32 to 50 grams/Liter \[G/L\]), alkaline phosphatase (20 to 125 international units/Liter \[IU/L\]), alanine aminotransferase \[ALT\] (0 to 48 IU/L), aspartate aminotransferase \[AST\] (0 to 55 IU/L), direct bilirubin (0 to 6 micromoles/liter \[umol/l\]), indirect bilirubin (0 to 22 umol/l), total bilirubin (0 to 22 umol/l), calcium (2.12 to 2.56 milimoles/liter \[mmol/l\]), chloride (95 to 108 mmol/l), carbon dioxide \[CO2\] content/bicarbonate (20 to 32 mmol/l), creatinine (67.2 to 129.1 umol/l), creatinine phosphokinase \[CPK\] (0 to 235 IU/L), gamma glutamyl transferase \[GGT\] (0 to75 IU/L), glucose (3.9 to 6.9 mmol/l), phosphorus (0.7 to 1.4 mmol/l), potassium (3.5 to 5.3 mmol/l), protein total (58 to 81 G/L), sodium (135 to 146 mmol/l), urea nitrogen (2.5 to 10.5 mmol/l), uric acid (240 to 510 umol/l). Only categories with non-zero (high and low) values at any time post Baseline have been presented.
Time frame: Up to Day 168 (Visit 8)
Number of Participants With Abnormal Urinalysis Parameters by Dipstick Method
Urinalysis parameters assessed were urine ketones, urine bilirubin, urine glucose, urine leukocyte esterase test for detecting WBC and urine protein. In this dipstick test, the level of bilirubin, glucose, leukocyte esterase and protein in urine samples was recorded as negative, trace, 1+, 2+, and 3+ (the plus sign increases with a higher level of bilirubin, glucose, leukocyte esterase, or proteins in the urine: 1+=slightly positive, 2+=positive, 3+=high positive). Urine samples were collected for the measurement of urinalysis parameters by dipstick method up to Day 168 (Visit 8). Only categories with significant values have been presented. Only those participants with data available at the indicated time point were analyzed.
Time frame: Up to Day 168 (Visit 8)
Mean Urine Potential of Hydrogen (pH)
Urinary pH measurement is a routine part of urinalysis. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 to 6.0). Urine samples were collected for the measurement of urine pH up to Day 168 (Visit 8). Only categories with significant values have been presented. Only those participants with data available at the indicated time point were analyzed.
Time frame: Day 168 (Visit 8)
Change From Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score at Days 28, 84 and 168
The SGRQ is designed to measure health-related quality of life (HRQoL) in participants with diseases of airway obstruction with the use of 76 items grouped into three domains: symptoms, activity and impact. The questions are designed to be self-completed by the participant based on recall of the past 4 weeks. Domain score =sum of the weighted scores for the non-missing items within each domain/maximum possible score for those non-missing items x 100. The SGRQ total score= sum of the weighted scores from all 76 items /maximum possible score for the SGRQ x100. Scores range from 0, representing the best possible health status, to 100, representing the worst possible health status. A decrease in score indicates an improvement in HRQoL whereas increase indicates deterioration in HRQoL. Baseline was the most recent recorded value before dosing on Day 1 at schedule visit. Change from Baseline was calculated by subtracting the value on-treatment from the Baseline value.
Time frame: Baseline (Day 1) and Day 28, Day 84 and Day 168
Change From Baseline in Chronic Obstructive Pulmonary Disease (COPD) Assessment Test (CAT) Score at Days 28, 84 and 168
The CAT is an 8-item, participant-completed instrument that covers symptoms such as cough, phlegm, chest tightness and breathlessness, and disease impacts including physical activity, confidence, sleep and energy. The CAT asks participant to score each item according to their current experience; there is no specific recall period. Items are scored on a 6-point response scale, with a score of 0 representing the participants are not experiencing the symptom/impact at all and a score of 5 representing a maximal symptom or impact. All items have equal weighting and so the total score is simply the sum of all scores and can range from 0 to a maximum of 40, with higher scores indicating a worse health state while a decrease in score indicates an improvement in health status. Baseline was the most recent recorded value before dosing on Day 1 at schedule visit. Change from Baseline was calculated by subtracting the value on-treatment from the Baseline value.
Time frame: Baseline (Day 1) and Days 28, 84 and 168
Number of Participants With Healthcare Resource Utilization Status
The total number of participants with visits for each type of healthcare contact ( office/practice visits, urgent care/outpatient clinic visits, emergency room visits and the intensive care visit and general wards visit have been presented.
Time frame: Up to Day 169 (Visit 9)
Number of Days Requiring Admission to Intensive Care Unit and General Ward
The total number of days requiring admission to intensive care unit and general ward have been presented.
Time frame: Up to Day 169 (Visit 9)
The study was conducted from 09 May 2016 to 08 November 2017 at 26 centers (21 centers in China and 5 centers in the Republic of Korea). A total of 306 participants were included in the Modified Intent-To-Treat (MITT) Population which comprised of all participants randomized to treatment who received at least one dose of study medication.
| Milestone | Placebo | UMEC 62.5 mcg |
|---|---|---|
| Started | 101 | 205 |
| Completed | 80 | 177 |
| Not completed | 21 | 28 |
| Withdrew: Lack of efficacy | 11 | 15 |
| Withdrew: Withdrawal by subject | 5 | 6 |
| Withdrew: Adverse event | 4 | 5 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Protocol defined stopping criteria | 0 | 1 |
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on Treatment Day 169 was defined as the mean of the FEV1 values obtained 23 and 24 hours after dosing on Treatment Day 168 (i.e. at Week 24). Baseline FEV1 is defined as the mean of the two assessments made pre-dose at Visit 2 (Day 1). Change from Baseline was calculated by subtracting the value on-treatment from the Baseline value. Modified intent-to-treat (mITT) Population comprised of all participants randomized to treatment who received at least one dose of the study medication in the treatment period.
| Liters | Placebo | UMEC 62.5 mcg |
|---|---|---|
| Change From Baseline in Trough (Pre-bronchodilator) Forced Expiratory Volume in 1 Second (FEV1) on Treatment Day 169 | -0.022 ± 0.0171 | 0.131 ± 0.0117 |
The Baseline Dyspnea Index (BDI) is used to measure the severity of dyspnea in participants at Baseline . The TDI measures changes in dyspnea severity from Baseline, as established by the BDI. TDI is formed of 3 individual scales that assess change in functional impairment, change in magnitude of task and change in magnitude of effort. The instrument is scored on a 7-point scale from -3 (major deterioration) to +3 (major improvement) for each category. Total scores (3 categories) range from -9 to +9 with lower scores indicating more deterioration in the severity of dyspnoea. A change of \>=1 units is considered to be the minimum clinically important difference (MCID) for the TDI.
| Scores on a scale | Placebo | UMEC 62.5 mcg |
|---|---|---|
| Transition Dyspnea Index (TDI) Focal Score at Week 24 (Day 168) | 1.6 ± 0.26 | 2.5 ± 0.17 |
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Weighted mean FEV1 was calculated over the nominal 0 to 6 hour post dose period. Values from post-dose assessments which were actually before the time of dosing were excluded from the calculation. The 0 hour value is the average value obtained 30 minutes and 5 minutes pre-dose, and both the 0 hour and 6 hour values must be present for a 0- to 6 hour weighted mean to be calculated. The 0 -to 6 hour weighted mean was derived by calculating the area under the FEV1 curve over the nominal time points of 0 hour, 15 and 30 minutes, 1, 3 and 6 hours, using the trapezoidal rule, and then dividing by the actual time between dosing and the 6 hour assessment. Baseline value for FEV1 was calculated from the values measured 30 minutes and 5 minutes pre-dose on Day 1. Change from Baseline was calculated by subtracting the value on-treatment from the Baseline value.
| Liters | Placebo | UMEC 62.5 mcg |
|---|---|---|
| Change From Baseline in Weighted Mean FEV1 Over 0 to 6 Hours Post-dose on Day 1 | 0.011 ± 0.0091 | 0.136 ± 0.0064 |
AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant or is associated with liver injury and impaired liver function.
| Participants | Placebo | UMEC 62.5 mcg |
|---|---|---|
| AE | 56 | 122 |
| SAE | 9 | 17 |
Vital signs (SBP and DBP) were obtained after participants had rested for approximately 5 minutes and before performing electrocardiogram (ECG) and spirometry testing. A single set of values was obtained. Baseline was the most recent recorded value before dosing on Day 1 at schedule visit. Change from Baseline was calculated by subtracting the value on-treatment from the Baseline value. Anytime post-Baseline values have been presented for SBP and DBP respectively.
| Millimeters of mercury | Placebo | UMEC 62.5 mcg |
|---|---|---|
| SBP, Anytime post-Baseline | 11.1 ± 11.25 | 11.4 ± 10.64 |
| DBP, Anytime post-Baseline | -10.2 ± 7.55 | -10.8 ± 8.03 |
Vital sign pulse rate was obtained after participants had rested for approximately 5 minutes and before performing electrocardiogram (ECG) and spirometry testing. A single set of values was obtained. Baseline was the most recent recorded value before dosing on Day 1 at schedule visit. Change from Baseline was calculated by subtracting the value on-treatment from the Baseline value. Anytime post-Baseline values have been presented for pulse rate.
| Beats/minute | Placebo | UMEC 62.5 mcg |
|---|---|---|
| Change From Baseline in Vital Sign Parameter: Pulse Rate | 10.7 ± 10.94 | 8.2 ± 9.47 |
A 12-lead ECG measurement was obtained after measurement of vital signs and before spirometry testing. Participants should be placed in the supine position for the ECG measurements. Any ECG abnormality recorded by a participant after the start of study treatment was included in the any-time post-Baseline record of all ECG abnormalities. Partcipants with abnormal ECG interpretation have been presented.
| Participants | Placebo | UMEC 62.5 mcg |
|---|---|---|
| Number of Participants With Electrocardiogram (ECG) Abnormalities Any Time Post Baseline | 51 | 105 |
Hematology parameters included basophils (normal range 0 to 0.2 giga cells/Liter), eosinophils (0.05 to 0.55 giga cells/Liter), hematocrit (0.36 to 0.49 percentage of red blood cells in blood), hemoglobin (118 to 168 gram/Liter), lymphocytes (0.85 to 4.1 giga cells/Liter), monocytes (0.2 to 1.1 giga cells/Liter), platelet count (PC)(130 to 400 giga cells/Liter), neutrophils (1.8 to 8 giga cells/Liter), total neutrophils (TN) (1.8 to 8 giga cells/Liter), white blood cell \[WBC\] count (3.8 to 10.8 giga cells/Liter). Only categories with non-zero (high and low) values at any time post Baseline have been presented.
| Participants | Placebo | UMEC 62.5 mcg |
|---|---|---|
| Eosinophils, Any time post Baseline, High,n=96,196 | 8 | 11 |
| Eosinophils, Any time post Baseline, Low,n=96,196 | 19 | 37 |
| Hematocrit, Any time post Baseline, High,n=96,196 | 14 | 35 |
| Hematocrit, Any time post Baseline, Low,n=96,196 | 3 | 21 |
| Hemoglobin, Any time post Baseline, High,n=96,196 | 2 | 5 |
| Hemoglobin, Any time post Baseline, Low,n=96,196 | 7 | 28 |
| Lymphocytes, Any time post Baseline, High,n=96,196 | 1 | 3 |
| Lymphocytes, Any time post Baseline, Low,n=96,196 | 3 | 10 |
| Monocytes, Any time post Baseline, High,n=96,196 | 0 | 1 |
| Monocytes, Any time post Baseline, Low,n=96,196 | 14 | 28 |
| PC, Any time post Baseline, High, n=96,195 | 1 | 0 |
| PC, Any time post Baseline, Low, n=96,195 | 7 | 15 |
| Neutrophils, Any time post Baseline, High,n=96,196 | 8 | 12 |
| Neutrophils,Any time post Baseline, Low,n=96,196 | 0 | 2 |
| TN, Any time post Baseline, High, n=96,196 | 8 | 12 |
| TN, Any time post Baseline, Low, n=96,196 | 0 | 2 |
| WBC count, Any time post Baseline, High,n=96,196 | 7 | 12 |
| WBC count, Any time post Baseline, Low,n=96,196 | 0 | 1 |
Clinical chemistry parameters assessed included albumin (normal range 32 to 50 grams/Liter \[G/L\]), alkaline phosphatase (20 to 125 international units/Liter \[IU/L\]), alanine aminotransferase \[ALT\] (0 to 48 IU/L), aspartate aminotransferase \[AST\] (0 to 55 IU/L), direct bilirubin (0 to 6 micromoles/liter \[umol/l\]), indirect bilirubin (0 to 22 umol/l), total bilirubin (0 to 22 umol/l), calcium (2.12 to 2.56 milimoles/liter \[mmol/l\]), chloride (95 to 108 mmol/l), carbon dioxide \[CO2\] content/bicarbonate (20 to 32 mmol/l), creatinine (67.2 to 129.1 umol/l), creatinine phosphokinase \[CPK\] (0 to 235 IU/L), gamma glutamyl transferase \[GGT\] (0 to75 IU/L), glucose (3.9 to 6.9 mmol/l), phosphorus (0.7 to 1.4 mmol/l), potassium (3.5 to 5.3 mmol/l), protein total (58 to 81 G/L), sodium (135 to 146 mmol/l), urea nitrogen (2.5 to 10.5 mmol/l), uric acid (240 to 510 umol/l). Only categories with non-zero (high and low) values at any time post Baseline have been presented.
| Participants | Placebo | UMEC 62.5 mcg |
|---|---|---|
| ALT, Any time post Baseline, High | 5 | 5 |
| Albumin, Any time post Baseline, High | 0 | 1 |
| Albumin, Any time post Baseline, Low | 0 | 1 |
| Alkaline Phosphatase, Any time post Baseline, High | 3 | 5 |
| Alkaline Phosphatase, Any time post Baseline, Low | 0 | 1 |
| AST, Any time post Baseline, High | 0 | 3 |
| Calcium, Any time post Baseline, Low | 2 | 1 |
| CO2 content,Any time post Baseline, Low | 6 | 26 |
| Chloride, Any time post Baseline, High | 0 | 8 |
| Chloride, Any time post Baseline, Low | 2 | 2 |
| Creatine Kinase, Any time post Baseline, High | 4 | 4 |
| Creatinine, Any time post Baseline, High | 0 | 1 |
| Creatinine, Any time post Baseline, Low | 20 | 51 |
| Direct Bilirubin, Any time post Baseline, High | 1 | 4 |
| GGT, Any time post Baseline, High | 10 | 12 |
| Glucose, Any time post Baseline, High | 23 | 46 |
| Glucose, Any time post Baseline, Low | 2 | 1 |
| Indirect Bilirubin, Any time post Baseline, High | 2 | 5 |
| Phosphorus, Any time post Baseline, High | 9 | 8 |
| Phosphorus, Any time post Baseline, Low | 3 | 5 |
| Potassium, Any time post Baseline, High | 1 | 1 |
| Potassium, Any time post Baseline, Low | 4 | 4 |
| Sodium, Any time post Baseline, High | 1 | 1 |
| Sodium, Any time post Baseline, Low | 1 | 4 |
| Total Bilirubin, Any time post Baseline, High | 4 | 8 |
| Total Protein, Any time post Baseline, High | 1 | 2 |
| Total Protein, Any time post Baseline, Low | 0 | 1 |
| Urea nitrogen, Any time post Baseline, High | 5 | 5 |
| Urea nitrogen, Any time post Baseline, Low | 2 | 1 |
| Uric acid, Any time post Baseline, High | 6 | 13 |
| Uric acid, Any time post Baseline, Low | 13 | 10 |
Urinalysis parameters assessed were urine ketones, urine bilirubin, urine glucose, urine leukocyte esterase test for detecting WBC and urine protein. In this dipstick test, the level of bilirubin, glucose, leukocyte esterase and protein in urine samples was recorded as negative, trace, 1+, 2+, and 3+ (the plus sign increases with a higher level of bilirubin, glucose, leukocyte esterase, or proteins in the urine: 1+=slightly positive, 2+=positive, 3+=high positive). Urine samples were collected for the measurement of urinalysis parameters by dipstick method up to Day 168 (Visit 8). Only categories with significant values have been presented. Only those participants with data available at the indicated time point were analyzed.
| Participants | Placebo | UMEC 62.5 mcg |
|---|---|---|
| Urine Bilirubin, Day 168, 1+ | 2 | 2 |
| Urine Bilirubin, Day 168, 2+ | 1 | 0 |
| Urine Glucose, Day 168, 1+ | 3 | 6 |
| Urine Glucose, Day 168, 2+ | 2 | 1 |
| Urine Glucose, Day 168, 3+ | 2 | 2 |
| Urine Glucose, Day 168, Trace | 2 | 2 |
| Urine leukocyte esterase, Day 168, 1+ | 1 | 1 |
| Urine leukocyte esterase, Day 168, 2+ | 0 | 2 |
| Urine leukocyte esterase, Day 168, Trace | 4 | 2 |
| Urine protein, Day 168, 1+ | 2 | 1 |
| Urine protein, Day 168, 2+ | 1 | 0 |
| Urine protein, Day 168, Trace | 10 | 6 |
Urinary pH measurement is a routine part of urinalysis. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 to 6.0). Urine samples were collected for the measurement of urine pH up to Day 168 (Visit 8). Only categories with significant values have been presented. Only those participants with data available at the indicated time point were analyzed.
| pH | Placebo | UMEC 62.5 mcg |
|---|---|---|
| Mean Urine Potential of Hydrogen (pH) | 6.16 ± 0.520 | 6.25 ± 0.632 |
The SGRQ is designed to measure health-related quality of life (HRQoL) in participants with diseases of airway obstruction with the use of 76 items grouped into three domains: symptoms, activity and impact. The questions are designed to be self-completed by the participant based on recall of the past 4 weeks. Domain score =sum of the weighted scores for the non-missing items within each domain/maximum possible score for those non-missing items x 100. The SGRQ total score= sum of the weighted scores from all 76 items /maximum possible score for the SGRQ x100. Scores range from 0, representing the best possible health status, to 100, representing the worst possible health status. A decrease in score indicates an improvement in HRQoL whereas increase indicates deterioration in HRQoL. Baseline was the most recent recorded value before dosing on Day 1 at schedule visit. Change from Baseline was calculated by subtracting the value on-treatment from the Baseline value.
| Scores on a scale | Placebo | UMEC 62.5 mcg |
|---|---|---|
| Day 28, n=91,188 | -1.45 ± 1.174 | -5.84 ± 0.813 |
| Day 84, n= 84,183 | -2.46 ± 1.268 | -7.05 ± 0.860 |
| Day 168, n=78,176 | -4.31 ± 1.316 | -7.34 ± 0.882 |
The CAT is an 8-item, participant-completed instrument that covers symptoms such as cough, phlegm, chest tightness and breathlessness, and disease impacts including physical activity, confidence, sleep and energy. The CAT asks participant to score each item according to their current experience; there is no specific recall period. Items are scored on a 6-point response scale, with a score of 0 representing the participants are not experiencing the symptom/impact at all and a score of 5 representing a maximal symptom or impact. All items have equal weighting and so the total score is simply the sum of all scores and can range from 0 to a maximum of 40, with higher scores indicating a worse health state while a decrease in score indicates an improvement in health status. Baseline was the most recent recorded value before dosing on Day 1 at schedule visit. Change from Baseline was calculated by subtracting the value on-treatment from the Baseline value.
| Scores on a scale | Placebo | UMEC 62.5 mcg |
|---|---|---|
| Day 28, n=94,199 | -0.26 ± 0.551 | -1.75 ± 0.378 |
| Day 84, n=87,189 | -0.08 ± 0.594 | -2.18 ± 0.403 |
| Day 168, n=80,179 | -1.32 ± 0.648 | -2.00 ± 0.434 |
The total number of participants with visits for each type of healthcare contact ( office/practice visits, urgent care/outpatient clinic visits, emergency room visits and the intensive care visit and general wards visit have been presented.
| Participants | Placebo | UMEC 62.5 mcg |
|---|---|---|
| Office/Practice Visits | 4 | 12 |
| Urgent Care/Outpatient Clinic Visits | 11 | 10 |
| Emergency Room Visits | 1 | 1 |
The total number of days requiring admission to intensive care unit and general ward have been presented.
| Days | Placebo | UMEC 62.5 mcg |
|---|---|---|
| Days in Intensive Care Unit | 0 | 0 |
| Days in General Ward | 35 | 20 |
Collected over AE and nSAE were collected from Day 1 to Day 178. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/101 (0%) | 9/101 (8.9%) | 32/101 (31.7%) |
| UMEC 62.5 mcg | 1/205 (0.5%) | 17/205 (8.3%) | 52/205 (25.4%) |
| Event | Placebo | UMEC 62.5 mcg |
|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 5/101 | 5/205 |
| PneumoniaInfections and infestations | 1/101 | 2/205 |
| Lung infectionInfections and infestations | 1/101 | 0/205 |
| ConcussionInjury, poisoning and procedural complications | 1/101 | 0/205 |
| Type 2 diabetes mellitusMetabolism and nutrition disorders | 1/101 | 1/205 |
| CataractEye disorders | 1/101 | 0/205 |
| Pulmonary tuberculosisInfections and infestations | 0/101 | 1/205 |
| Chest painGeneral disorders | 0/101 | 1/205 |
| Sudden deathGeneral disorders | 0/101 | 1/205 |
| Cervical vertebral fractureInjury, poisoning and procedural complications | 0/101 | 1/205 |
| Event | Placebo | UMEC 62.5 mcg |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 13/101 | 25/205 |
| NasopharyngitisInfections and infestations | 11/101 | 19/205 |
| Urinary tract infectionInfections and infestations | 3/101 | 2/205 |
| Blood glucose increasedInvestigations | 3/101 | 2/205 |
| Benign prostatic hyperplasiaReproductive system and breast disorders | 3/101 | 0/205 |
| DizzinessNervous system disorders | 2/101 | 6/205 |
| Age, Continuous(Years) | Placebo | UMEC 62.5 mcg | Total |
|---|---|---|---|
| Mean | 65.7 ± 7.05 | 65.5 ± 6.89 | 65.6 ± 6.93 |
| Sex: Female, Male(Participants) | Placebo | UMEC 62.5 mcg | Total |
|---|---|---|---|
| Female | 4 | 12 | 16 |
| Male | 97 | 193 | 290 |
| Race/Ethnicity, Customized(Participants) | Placebo | UMEC 62.5 mcg | Total |
|---|---|---|---|
| Asian - East Asian Heritage | 101 | 205 | 306 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from May 2016 to primary completion in Nov 2017, 17 months.
Results were first posted in Jun 2019, 1 year 7 months after primary completion.
Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 17 months is below that.
Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Umeclidinium bromide
Pulmonary Disease, Chronic Obstructive →